

REMARKS

Reconsideration of this application is respectfully requested.

Claims 1-71 have been presented for examination. The Examiner required restriction of the claims. Specifically, the Examiner divided the subject matter of the claims into the following four groups:

Group I, claims 1-45 and 62, drawn to the use of a modulator blocker to modulate the binding of an effector molecule to a DC-SIGN receptor;

Group II, claims 46-55 and 71, drawn to a pharmaceutical composition;

Group III, claims 56-61, drawn to a method of identifying a DC-SIGN blocker; and

Group IV, claims 63-70, drawn to a method of targeting a subject molecule to a cell using a DC-SIGN blocker.

Applicant elects the claims of Group III, claims 56-61, drawn to a method of identifying a DC-SIGN blocker. Claims 56-61 are readable on the elected inventions.

Finally, Applicant apprises the Examiner of related application Serial No. 10/700,491.

If there is any fee due in connection with the filing of this Response, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By:


Kenneth J. Meyers
Reg. No. 25,146
Phone: (202) 408-4033
Fax: (202) 408-4400
E-mail: ken.meyers@finnegan.com

Dated: April 25, 2008